VCNX Vaccinex, Inc. Net earnings per share growth this year

International scientific cooperation impacts the financial flows of Vaccinex, Inc. (VCNX), as evidenced by the annual percentage growth in net earnings per share. The current value of 0.00 captures the level of this metric. A capital deficit is triggering dilutive issuances, although demand for cancer and neurodegenerative disease therapies remains stable regardless of economic cycles.

Vaccinex (VCNX): Net earnings per share growth this year from 07/04/2022 to 12/28/2024

Analytical breakdowns and data insights for company Vaccinex Inc (VCNX)

- current quotes and average value forecast:

Market Chart Vaccinex Inc|VCNX - Price Target Chart

- market capitalization data:

Market Valuation Vaccinex, Inc.|VCNX - Total Company Value

- company book value details:

Accounting Value per Share Vaccinex|VCNX - Company Net Assets|Market Capitalization to Book Value Ratio vaccinex.com|VCNX - Aggregate Company Assets

- debt and liquidity details:

- net income and valuation ratios data:

VCNX - Net Profit|Expected Net Profit Vaccinex, Inc.|VCNX - Price to Earnings Ratio|Future Price to Earnings Multiple Vaccinex, Inc.|VCNX - PEG Multiple|EV/EBITDA Multiple Vaccinex, Inc.|VCNX - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Vaccinex|VCNX - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months vaccinex.com|VCNX - Net earnings per share growth this year|Net earnings per share growth forecast for next year Vaccinex, Inc.

- company sales and revenue statistics:

VCNX - Revenue and Sales Volume|Projected Sales Volume Vaccinex, Inc|VCNX - P/S Multiple|Forward Price-to-Revenue Multiple Vaccinex

Summary company analysis:VCNX (Vaccinex, Inc.)

Investors should evaluate the resilience of Vaccinex, Inc. (VCNX) through the lens of clinical success, as the development of therapies for neurodegenerative diseases remains independent of market cycles. Profit dynamics here reflect the effectiveness of attracting R&D partners and the pace of drug commercialization. By analyzing the relative change in EPS over the year, the user can see the percentage growth in net income per share, which helps identify the company's growth phase.

Key competitors